Recent 8-K filings for RXST

• May 6, 2026, 7:59 PM ET earnings materiality 0.80 negative item 2.02item 9.01 ◈ Earnings Releases

  RxSight Reports Q1 2026 Sales of $30.9M, Net Loss Widens, Reiterates Full-Year Guidance

  Q1 2026 sales of $30.9M, down 18.5% YoY, driven by 27,472 Light Adjustable Lens units sold.

• February 25, 2026, 6:59 PM ET earnings materiality 0.80 negative item 2.02item 9.01

  RxSight reports Q4 revenue down 19% YoY; 2025 net loss $(38.9M); issues weak 2026 guidance

  Q4 2025 revenue $32.6M (-19% YoY); LAL revenue -1%, LDD revenue -72%.

• January 12, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 5.02item 7.01item 9.01

  RxSight preliminary Q4 2025 revenue ~$32.6M, FY2025 revenue ~$134.5M above guidance; appoints Mark Wilterding CFO

  Q4 2025 revenue ~$32.6M; FY2025 revenue ~$134.5M vs prior guidance $125-130M.

• December 23, 2025, 6:59 PM ET leadership materiality 0.60 neutral item 5.02item 7.01item 9.01

  RxSight enters CFO transition agreement with Thunen; reaffirms 2025 outlook

  Shelley Thunen transitions from CFO; transition and consulting agreements executed effective Dec 23, 2025.

• December 22, 2025, 6:59 PM ET leadership materiality 0.60 neutral item 5.02item 7.01item 9.01

  RxSight CFO Shelley Thunen to transition; consulting agreement through Dec 2026

  CFO Shelley Thunen to depart by Jan 31, 2026 or upon appointment of successor; will serve as consultant thereafter.

• November 5, 2025, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  RxSight Q3 revenue down 14% YoY to $30.3M; net loss widens to $9.8M

  Revenue $30.3M (-14% YoY); LAL volume up 6% but LDD placements down 68%.

• August 7, 2025, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  RxSight Q2 revenue $33.6M (-4% YoY); net loss $(11.8)M; reaffirms FY2025 guidance

  Total revenue $33.6M, down 4% from $34.9M in Q2 2024; LAL units up 13%, LDD units down 49%.

• July 8, 2025, 7:59 PM ET earnings materiality 0.85 negative item 2.02item 9.01

  RxSight preliminary Q2 revenue $33.6M, down 4% YoY; cuts FY2025 guidance to $120-130M

  Preliminary Q2 revenue ~$33.6M, down 4% YoY and 11% sequentially; LAL volume +13% YoY, LDD sales -49% YoY.

• May 7, 2025, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  RxSight Q1 revenue $37.9M (+28% YoY); LAL volume up 36%

  Q1 revenue $37.9M (+28% YoY); LAL revenue +37%, LDD revenue +8%.

• April 3, 2025, 7:59 PM ET earnings materiality 0.80 negative item 2.02item 9.01

  RxSight preliminary Q1 revenue $37.9M (+28% YoY); cuts FY2025 guidance to $160M-$175M

  Preliminary Q1 2025 revenue ~$37.9M, up 28% YoY but down 6% QoQ; LAL procedure volume 27,579 (+36% YoY).

• February 25, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  RxSight Q4 revenue $40.2M (+41% YoY), LAL volume +61%; reaffirms FY2025 guidance

  Q4 revenue $40.2M (+41% YoY); full-year revenue $139.9M (+57% YoY).

• January 13, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  RxSight reports preliminary Q4/FY2024 rev ~$40.2M/$139.9M, +41%/+57% YoY; guides 2025 rev $185-197M

  Q4 2024 revenue ~$40.2M (+41% YoY); FY2024 ~$139.9M (+57% YoY).

• November 7, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  RxSight Q3 revenue $35.3M (+59% YoY); raises FY revenue guidance to $139-140M

  Revenue $35.3M, up 59% YoY; LAL procedures 24,554 (+80%), LDD installed base 888 (+51%).

• August 5, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  RxSight Q2 revenue $34.9M, +68% YoY; raises FY2024 guidance above prior range

  Revenue $34.9M in Q2 2024, up 68% from $20.8M in Q2 2023; LAL volume +92% to 24,214 lenses.

• May 9, 2024, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 8.01item 9.01 ◈ Material Agreements

  RxSight prices $100M public stock offering at $56/share for commercial expansion

  Offering of 1,785,714 shares at $56/share; underwriters have 30-day option for 267,857 additional shares.

• May 6, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  RxSight Q1 revenue $29.5M (+69% YoY), raises FY2024 guidance

  LAL volume up 92% to 20,218 units; LDD installed base reaches 732 (+61% YoY).

• February 28, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  RxSight Q4 revenue $28.6M (+78% YoY); LAL volume +98% YoY; guides FY2024 rev $128-135M

  Q4 2023 revenue $28.6M, up 78% YoY, with 77 LDDs sold and 18,071 LALs (+98% YoY).

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.72 · Most common event earnings

8 positive 6 negative 10 neutral

source · RXST on sec.gov